Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Nat Cancer. 2020 Jan 20;1(2):176–183. doi: 10.1038/s43018-019-0011-0

Fig. 3: Patients with ctDNA not detected after chemoradiation therapy (CRT) may not benefit from consolidation immune checkpoint inhibition (CICI).

Fig. 3:

a, Example of longitudinal CT imaging with sum of target lesion longest diameters measured according to RESIST 1.1 (RECIST SLD, right y-axis) and ctDNA concentrations (left y-axis) for a patient in the CICI cohort with ctDNA not detected after CRT. ctDNA remained not detected early on-CICI and at last follow-up with no evidence of disease. Tumors are outlined in blue on the CT images. A total of 10 patients in the CICI cohort had similar ctDNA testing and clinical outcomes. b, Example of longitudinal CT imaging and ctDNA concentrations for the one patient in the CICI cohort with ctDNA not detected after CRT who developed grade 5 pneumonitis during CICI. Pneumonitis is outlined in orange on the CT image. c, Kaplan-Meier analysis of freedom from progression in patients with ctDNA not detected pre-CICI treated with CICI (n=13) and patients with ctDNA not detected post-CRT treated without CICI (n=12). P value was calculated using a two-sided log-rank test.